ICON Public Limited Company · ICLR · FY2026 Q3 · Calendar Q4 2026

ICON: bookings and margins improve as revenue dips

ICON's strong bookings, margin expansion, and continued technology investment support an improving operating trajectory, but revenue decline, pass-through volatility, and booking-to-revenue conversion remain important constraints.

Reported After market closeNASDAQHealthcare $14.12B market cap
80quality score

Earnings scorecard

Reported versus consensus
Reported EPS — Consensus $2.66
EPS surprise — Reported versus consensus
Reported revenue — Consensus $2.01B
Revenue surprise — Reported versus consensus

Market reaction

close-to-close (session unavailable)
Stock move +12.5% Event window
SPY move +0.2% Same window
Abnormal move +12.4% Stock minus SPY
Volume 0.5× Versus trailing sessions
Subsequent drift 0.0% Up to 20 sessions
ICLRSPY benchmark

Ask FN2 about ICLR FY2026 Q3

Transcript, numbers and history already loaded
What drove ICLR's +12.5% move after FY2026 Q3 earnings?What changed in ICLR's guidance and outlook in FY2026 Q3?Give me the bull and bear case for ICLR after FY2026 Q3 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior quarter's reaffirmed outlook and pass-through-related margin pressure, ICON reported margin expansion, record net business wins, a book-to-bill above 1.3x, narrowed 2026 guidance, and a mid-single-digit revenue-growth outlook for 2027. Management also highlighted a new share-repurchase authorization and debt refinancing.

Guidance delta

Management narrowed 2026 guidance and indicated mid-single-digit revenue growth with higher-single-digit earnings growth for 2027.

Key takeaways

  • Adjusted EBITDA grew 3% to $337 million, with margin expansion of 70 basis points.
  • Revenue dipped 2.9% year over year, while free cash flow remained robust at $302 million.
  • Net business wins reached $3.15 billion, and trailing-twelve-month book-to-bill exceeded 1.3x.
  • Management highlighted AI-enabled tools, biotech partnerships, a $750 million share-repurchase authorization, and a $2.15 billion bond issuance.

Management priorities

  • Recover and grow direct-fee services.
  • Continue organic investment in AI and technology platforms.
  • Expand the biotech partnership ecosystem and therapeutic expertise.
  • Pursue selective M&A and ongoing capital returns.

Follow ICLR with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Company context

Snapshot as of publication

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.…

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
AVTR Avantor, Inc. FY2026 Q3 · Calendar Q4 2026 — -2.2% Avantor reports stronger growth and raises full-year guidance
IQV IQVIA Holdings Inc. FY2026 Q3 · Calendar Q4 2026 +2.5% -0.7% IQVIA: AI momentum and bookings support raised 2026 outlook
CNC Centene Corp. FY2026 Q3 · Calendar Q4 2026 +506.1% +1.0% Centene raises EPS outlook as Medicaid remains stable
HCA HCA Healthcare, Inc. FY2026 Q3 · Calendar Q4 2026 +8.6% -3.3% HCA Q3: Volume growth offsets payer-mix and Medicaid pressure
RGEN Repligen Corporation FY2026 Q3 · Calendar Q4 2026 +14.5% -2.4% Repligen: Record Q3, Higher Guidance, BioLife Integration
NVS Novartis AG FY2026 Q3 · Calendar Q4 2026 +9.3% +2.0% Novartis Q3 2026: Growth, Margin Expansion and Higher Guidance

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the ICLR recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-10-28T14:07:37.761317+00:00
  2. FN2 earnings calendar · 2026-10-08T01:23:11.508792+00:00
  3. Polygon adjusted daily market bars · 2026-10-28T14:30:44.594185+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-28T14:30:44.591427+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-28. For educational purposes only; not investment advice.